Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene

Anaesthesia

Volumn 67, Issue 9, 2012, Pages 1021-1024

  Russell, T ^a   Riazi, S ^b   Kraeva, N ^b   Steel, A C ^b   Hawryluck, L A ^c  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CAFFEINE; CREATINE KINASE; DANTROLENE; GENOMIC DNA; HALOPERIDOL; HALOTHANE; RYANODINE RECEPTOR 1;

ADULT; ARTICLE; CALCIUM TRANSPORT; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; GENE SEQUENCE; HUMAN; LIQUID CHROMATOGRAPHY; MALIGNANT HYPERTHERMIA; MASS SPECTROMETRY; MOTHER; MULTIPLE ORGAN FAILURE; NEUROLEPTIC MALIGNANT SYNDROME; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RECEPTOR GENE; RHABDOMYOLYSIS; SARCOPLASMIC RETICULUM; TREATMENT RESPONSE;

ANESTHETICS, INHALATION; ANTIPSYCHOTIC AGENTS; BODY TEMPERATURE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATINE KINASE; DANTROLENE; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; GENETIC VARIATION; HALLUCINOGENS; HALOPERIDOL; HALOTHANE; HUMANS; MULTIPLE ORGAN FAILURE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROLEPTIC MALIGNANT SYNDROME; RECURRENCE; RHABDOMYOLYSIS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SPECTRUM ANALYSIS; YOUNG ADULT;

EID: 84864653972     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2012.07226.x     Document Type: Article

References (25)

1. Kraev N, Loke JC, Kraev A, MacLennan DH,. Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes. Anesthesiology 2003; 99: 289-96. (Pubitemid 36909554)
2. Kraeva N, Riazi S, Loke J, et al. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Canadian Journal of Anesthesia 2011; 58: 504-13.
3. (accessed 10/09/2012).
4. Larach MG,. Standardization of the caffeine halothane muscle contracture test: North American Malignant Hyperthermia Group. Anesthesia and Analgesia 1989; 69: 511-5.
5. Carvalho M, Pontes H, Remião F,. Mechanisms underlying the hepatotoxic effects of ecstasy. Current Pharmaceutical Biotechnology 2010; 11: 476.
6. Andreu V, Mas A, Bruguera M,. Ecstasy: a common cause of severe acute hepatotoxicity. Journal of Hepatology 1998; 29: 394.
7. Lehmann ED, Thom CH, Croft DN,. Delayed severe rhabdomyolysis after taking 'ecstasy'. Postgraduate Medical Journal 1995; 71: 186-8.
8. Halachanova V, Sansone RA, McDonald S,. Delayed Rhabdomyolysis After Ecstasy Use. Mayo Clinic Proceedings 2001; 76: 112-3.
9. Henry JA, Jeffreys KJ, Dawling S,. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (ecstasy). Lancet 1992; 340: 384-7.
10. Hall AP, Henry JA,. Acute toxic effects of "ecstacy" (MDMA) and related compounds: overview of pathophysiology and clinical management. British Journal of Anaesthesia 2006; 96: 678-85. (Pubitemid 43786681)
11. Regenthal R, Kruger M, Rudolph K, Trauer H, Preiss R,. Survival after massive "ecstacy" (MDMA) ingestion. Intensive Care Medicine 1999; 25: 640-641. (Pubitemid 29312605)
12. Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M,. Multiple toxicity from 3,4-methylenedioxymethamphetamin (ecstasy). American Journal of Emergency Medicine 2003; 21: 121-4.
13. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. Journal of Pharmacology and Experimental Therapeutics 1999; 290: 136-45. (Pubitemid 29302313)
14. de la Torre R, Farre M, Roset PN,. Human pharmacology of MDMA: pharmacokinetics, metabolism and disposition. Therapeutic Drug Monitoring 2004; 26: 137-44. (Pubitemid 38501207)
15. Schifano F,. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychpharmacology 2004; 173: 242-8. (Pubitemid 38703797)
16. Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU,. Fatal MDMA intoxication. Lancet 1999; 353: 593-4.
17. de la Torre R, Farre M, Ortuno J,. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. British Journal of Clinical Pharmacology 2000; 49: 104-9. (Pubitemid 30068287)
18. Larner A,. Dantrolene and 'cstasy' overdose. Anaesthesia 1993; 48: 179-80.
19. Stone R,. Treatment of "ecstasy" overdose with dantrolene. Anaesthesia 1993; 48: 83.
20. Sato T, Nishio H, Iwata M, et al. Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Science International 2010; 194: 77-9.
21. Allen G, Larach M, Kunselman A,. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. Anesthesiology 1998; 88: 579-88. (Pubitemid 28120189)
22. European Malignant Hyperthermia Group (EMHG). (accessed 14/3/2012).
23. Tong J, Oyamada H, Demaurex N, Grinstein S, McCarthy TV, DH M,. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. Journal of Biological Chemistry 1997; 272: 26332-9. (Pubitemid 27458847)
24. Grunau BE, Wiens MO, Brubacher JR,. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. Canadian Journal of Emergency Medicine 2010; 12: 435-42.
25. Brandom BW, Larach MG, Chen MSA, Young MC,. Complications associated with the administration of dantrolene 1987 to 2006: A report from the North American Malignant Hyperthermia registry of the Malignant Hyperthermia Association of the United States. Anesthesia and Analgesia 2011; 112: 1115-23.